Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA.
Pediatr Pulmonol. 2012 Nov;47(11):1113-22. doi: 10.1002/ppul.22543. Epub 2012 Apr 11.
Accelerated lung function decline in cystic fibrosis (CF) is associated with mucoid Pseudomonas aeruginosa infection. Recent data suggest that mucoid P. aeruginosa may amenable to elimination from the airway. We aim to determine whether the initiation of an aggressive antibiotic eradication regimen upon initial discovery of mucoid P. aeruginosa in the CF airway could be successful in clearing the organism from the CF lung.
We performed a retrospective analysis of patients with CF who demonstrated new growth of mucoid P. aeruginosa in an airway culture between January 2003 and December 2008. The primary endpoint was clearance of mucoid P. aeruginosa, based upon the Leeds criteria, with no further growth of mucoid P. aeruginosa cultures within 12 months of the initial discovery and treatment. Factors associated with successful clearance were also evaluated.
Forty-eight of 355 patients with CF had a new diagnosis of mucoid P. aeruginosa during the study period; 15 patients underwent an eradication attempt, while 33 patients received no increase in therapy. We observed clearance of mucoid P. aeruginosa in 73.3% of patients undergoing an eradication attempt, whereas 36.6% of those that did not undergo attempted eradication cleared the organism at 1 year (P < 0.05). Prolonged mucoid P. aeruginosa airway clearance (>24 months) for mucoid P. aeruginosa was seen in 60.0% in subjects undergoing eradication compared to 21.2% (P = 0.02) in control patients. At the study conclusion, lung function was greater in subjects who underwent an eradication attempt than in patients who did not undergo an eradication attempt (FEV(1) %: 91.7% vs. 75.0%, P = 0.04).
Clearance of initial mucoid P. aeruginosa from the airways of select patients with CF is possible with current antibiotic regimens, and the attempt may be associated with improved lung function.
囊性纤维化(CF)中肺功能的加速下降与粘液性铜绿假单胞菌感染有关。最近的数据表明,粘液性铜绿假单胞菌可能易于从气道中消除。我们旨在确定在 CF 气道中首次发现粘液性铜绿假单胞菌时,启动积极的抗生素消除方案是否能成功地从 CF 肺中清除该生物体。
我们对 2003 年 1 月至 2008 年 12 月期间在气道培养物中发现新生长的粘液性铜绿假单胞菌的 CF 患者进行了回顾性分析。主要终点是根据利兹标准清除粘液性铜绿假单胞菌,在初始发现和治疗后 12 个月内不再生长粘液性铜绿假单胞菌培养物。还评估了与成功清除相关的因素。
在研究期间,355 例 CF 患者中有 48 例新诊断为粘液性铜绿假单胞菌;15 例患者进行了消除尝试,而 33 例患者未增加治疗。我们观察到在进行消除尝试的患者中,73.3%的患者清除了粘液性铜绿假单胞菌,而未进行消除尝试的患者中,有 36.6%的患者在 1 年内清除了该生物体(P <0.05)。在进行消除尝试的患者中,粘液性铜绿假单胞菌气道清除时间延长(>24 个月)的比例为 60.0%,而对照组患者为 21.2%(P=0.02)。在研究结束时,进行消除尝试的患者的肺功能比未进行消除尝试的患者更高(FEV1%:91.7%对 75.0%,P=0.04)。
通过目前的抗生素方案,可以从选择的 CF 患者的气道中清除初始粘液性铜绿假单胞菌,并且尝试可能与改善肺功能有关。